FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...
Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.
The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of ...
GlobalData on MSN17d
Sanofi’s Phase III CSU treatment trial meets endpointsSanofi has reported that its Phase III LIBERTY-CUPID Study C of Dupixent (dupilumab) in patients with chronic spontaneous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback